Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Tuesday, July 11th, Marketbeat reports. They currently have a $2.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 92.31% from the company’s current price.

Separately, Canaccord Genuity set a $3.00 price objective on Inotek Pharmaceuticals Corporation and gave the stock a “buy” rating in a research report on Monday, June 26th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Inotek Pharmaceuticals Corporation presently has an average rating of “Hold” and an average target price of $3.80.

Shares of Inotek Pharmaceuticals Corporation (ITEK) traded up 6.67% on Tuesday, reaching $1.04. 1,003,865 shares of the company’s stock traded hands. The company’s market cap is $28.07 million. Inotek Pharmaceuticals Corporation has a 12-month low of $0.85 and a 12-month high of $9.78. The stock has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.67.

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.23. Equities research analysts anticipate that Inotek Pharmaceuticals Corporation will post ($1.33) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by HC Wainwright” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/07/inotek-pharmaceuticals-corporation-nasdaqitek-rating-lowered-to-neutral-at-hc-wainwright-updated-updated-updated.html.

Institutional investors have recently made changes to their positions in the stock. LMR Partners LLP purchased a new stake in Inotek Pharmaceuticals Corporation during the second quarter valued at $126,000. Goldman Sachs Group Inc. increased its stake in Inotek Pharmaceuticals Corporation by 276.0% in the first quarter. Goldman Sachs Group Inc. now owns 58,758 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 43,131 shares during the last quarter. Minerva Advisors LLC purchased a new stake in Inotek Pharmaceuticals Corporation during the first quarter valued at $126,000. Columbus Circle Investors increased its stake in Inotek Pharmaceuticals Corporation by 78.4% in the first quarter. Columbus Circle Investors now owns 385,229 shares of the biotechnology company’s stock valued at $770,000 after buying an additional 169,262 shares during the last quarter. Finally, Highbridge Capital Management LLC increased its stake in Inotek Pharmaceuticals Corporation by 183.2% in the fourth quarter. Highbridge Capital Management LLC now owns 90,947 shares of the biotechnology company’s stock valued at $554,000 after buying an additional 58,828 shares during the last quarter. 38.53% of the stock is owned by hedge funds and other institutional investors.

Inotek Pharmaceuticals Corporation Company Profile

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Receive News & Stock Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.